Dr. John Boyle, an Ear, Nose, and Throat physician at Wilmington Health, is approaching an important milestone in the treatment of obstructive sleep apnea (OSA), with nearly 50 patients treated using Inspire® therapy. Early outcomes from Dr. Boyle’s growing Inspire patient population have been highly encouraging, demonstrating both strong clinical effectiveness and meaningful improvements in patient quality of life.
Among the 38 patients who have completed the full Inspire therapy pathway, including the Fine Tune Sleep Study, results show an average apnea-hypopnea index (AHI) reduction of approximately 80 percent, slightly exceeding the national average. Patient adherence has also been excellent, averaging six hours of nightly use, and nearly all patients report significant subjective improvements in sleep quality, energy levels, and overall well-being.
In addition to these outcomes, Dr. Boyle has begun offering the latest advancement in Inspire therapy: the Inspire V System. This next-generation technology represents a meaningful evolution in care, featuring a more streamlined surgical procedure. The Inspire V System integrates the respiratory sensor directly into the implant, eliminating the need for a separate sensing lead while maintaining precise synchronization with the patient’s natural breathing pattern.
Inspire therapy is a mask-free solution designed for patients with moderate to severe obstructive sleep apnea who have tried and struggled with CPAP therapy. Implanted entirely within the body, the system works comfortably during sleep to keep the airway open by delivering gentle stimulation in harmony with breathing.
Clinical data continue to support Inspire therapy as a safe, effective, and highly satisfying treatment option. Studies show that 99.6 percent of Inspire implant procedures are completed without major complications, reflecting a strong safety profile (Suurna MV et al., Laryngoscope, 2021). Patient satisfaction remains high, with 93 percent of patients indicating they would recommend Inspire therapy to a friend or family member. Long-term efficacy has also been well documented, with Inspire therapy reducing sleep apnea events by an average of 79 percent (Woodson BT et al., Otolaryngology–Head and Neck Surgery, 2018).
Dr. Boyle’s early adoption of the Inspire V System and his growing experience with Inspire therapy underscore Wilmington Health’s commitment to offering innovative, patient-centered solutions for sleep apnea. As he approaches treatment of his 50th Inspire patient, the outcomes to date reflect both clinical excellence and a meaningful impact on patients’ lives.